Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

A Stevens; P Clayton; L Tatò; H W Yoo; M D Rodriguez-Arnao; J Skorodok; G R Ambler; M Zignani; J Zieschang; G Della Corte; B Destenaves; A Champigneulle; J Raelson; P Chatelain

doi:10.1038/tpj.2013.14

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

A Stevens, P Clayton, L Tatò, H W Yoo, M D Rodriguez-Arnao, J Skorodok, G R Ambler, M Zignani, J Zieschang, G Della Corte, B Destenaves, A Champigneulle, J Raelson, P Chatelain

Research output: Contribution to journal › Article › peer-review

Abstract

Individual responses to growth hormone (GH) treatment are variable. Short-term generation of insulin-like growth factor-I (IGF-I) is recognized as a potential marker of sensitivity to GH treatment. This prospective, phase IV study used an integrated genomic analysis to identify markers associated with 1-month change in IGF-I (ΔIGF-I) following initiation of recombinant human (r-h)GH therapy in treatment-naïve children with GH deficiency (GHD) (n=166) or Turner syndrome (TS) (n=147). In both GHD and TS, polymorphisms in the cell-cycle regulator CDK4 were associated with 1-month ΔIGF-I (P

Original language	English
Journal	The pharmacogenomics journal
Volume	14
Issue number	1
Early online date	9 Apr 2013
DOIs	https://doi.org/10.1038/tpj.2013.14
Publication status	Published - Feb 2014

Access to Document

10.1038/tpj.2013.14

Cite this

Stevens, A., Clayton, P., Tatò, L., Yoo, H. W., Rodriguez-Arnao, M. D., Skorodok, J., Ambler, G. R., Zignani, M., Zieschang, J., Della Corte, G., Destenaves, B., Champigneulle, A., Raelson, J., & Chatelain, P. (2014). Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. The pharmacogenomics journal, 14(1). https://doi.org/10.1038/tpj.2013.14

@article{95594554bf4c49c18b8fc181b3b5e175,

title = "Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.",

abstract = "Individual responses to growth hormone (GH) treatment are variable. Short-term generation of insulin-like growth factor-I (IGF-I) is recognized as a potential marker of sensitivity to GH treatment. This prospective, phase IV study used an integrated genomic analysis to identify markers associated with 1-month change in IGF-I (ΔIGF-I) following initiation of recombinant human (r-h)GH therapy in treatment-na{\"i}ve children with GH deficiency (GHD) (n=166) or Turner syndrome (TS) (n=147). In both GHD and TS, polymorphisms in the cell-cycle regulator CDK4 were associated with 1-month ΔIGF-I (P",

author = "A Stevens and P Clayton and L Tat{\`o} and Yoo, {H W} and Rodriguez-Arnao, {M D} and J Skorodok and Ambler, {G R} and M Zignani and J Zieschang and {Della Corte}, G and B Destenaves and A Champigneulle and J Raelson and P Chatelain",

year = "2014",

month = feb,

doi = "10.1038/tpj.2013.14",

language = "English",

volume = "14",

journal = "The pharmacogenomics journal",

issn = "1470-269X",

publisher = "Springer Nature",

number = "1",

}

Stevens, A, Clayton, P, Tatò, L, Yoo, HW, Rodriguez-Arnao, MD, Skorodok, J, Ambler, GR, Zignani, M, Zieschang, J, Della Corte, G, Destenaves, B, Champigneulle, A, Raelson, J & Chatelain, P 2014, 'Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.', The pharmacogenomics journal, vol. 14, no. 1. https://doi.org/10.1038/tpj.2013.14

TY - JOUR

T1 - Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

AU - Stevens, A

AU - Clayton, P

AU - Tatò, L

AU - Yoo, H W

AU - Rodriguez-Arnao, M D

AU - Skorodok, J

AU - Ambler, G R

AU - Zignani, M

AU - Zieschang, J

AU - Della Corte, G

AU - Destenaves, B

AU - Champigneulle, A

AU - Raelson, J

AU - Chatelain, P

PY - 2014/2

Y1 - 2014/2

N2 - Individual responses to growth hormone (GH) treatment are variable. Short-term generation of insulin-like growth factor-I (IGF-I) is recognized as a potential marker of sensitivity to GH treatment. This prospective, phase IV study used an integrated genomic analysis to identify markers associated with 1-month change in IGF-I (ΔIGF-I) following initiation of recombinant human (r-h)GH therapy in treatment-naïve children with GH deficiency (GHD) (n=166) or Turner syndrome (TS) (n=147). In both GHD and TS, polymorphisms in the cell-cycle regulator CDK4 were associated with 1-month ΔIGF-I (P

AB - Individual responses to growth hormone (GH) treatment are variable. Short-term generation of insulin-like growth factor-I (IGF-I) is recognized as a potential marker of sensitivity to GH treatment. This prospective, phase IV study used an integrated genomic analysis to identify markers associated with 1-month change in IGF-I (ΔIGF-I) following initiation of recombinant human (r-h)GH therapy in treatment-naïve children with GH deficiency (GHD) (n=166) or Turner syndrome (TS) (n=147). In both GHD and TS, polymorphisms in the cell-cycle regulator CDK4 were associated with 1-month ΔIGF-I (P

U2 - 10.1038/tpj.2013.14

DO - 10.1038/tpj.2013.14

M3 - Article

C2 - 23567489

SN - 1470-269X

VL - 14

JO - The pharmacogenomics journal

JF - The pharmacogenomics journal

IS - 1

ER -

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

Abstract

Access to Document

Fingerprint

Cite this